Researchers reported that obesity was associated with reduced numbers of Vδ2+ T cells in the blood. When stimulated in the laboratory, the cells from people with obesity were less active than those from comparison participants. The affected cells also displayed abnormalities in nutrient uptake and energy production, two processes that support the cellular demands of an effective immune response. These observations provide a potential cellular explanation for impaired immune responses in obesity, although the experiment does not establish that the metabolic changes directly caused the reduced cellular function.

The work focused on cells rather than demonstrating clinical protection against infection or cancer. Vδ2+ T cells are described in the research as part of the body’s early defense against infection and can identify and destroy certain cancer cells. The investigators therefore assessed both how these cells functioned after stimulation and how they obtained fuel and generated energy. The findings indicated that obesity disrupted important features of immune-cell metabolism, potentially limiting the resources available for a rapid response. The study used an experimental design, and its results concern biological responses measured in cells; they should not be interpreted by themselves as proof that surgery prevents disease in patients.

After Roux-en-Y gastric bypass, or RYGB, participants showed significant improvement in the metabolic processes that support immune-cell function. The surgery was also followed by a marked recovery in the cells’ capacity to respond to stimulation. The researchers concluded that the metabolic and functional defects detected in obesity were reversed following the procedure. Because the supplied report does not describe the number of participants, duration of follow-up, effect estimates, or the design of any comparison involving surgery, it does not establish the size or durability of the treatment effect or support broad clinical recommendations.

The research was conducted by Dr Ciara Flynn of Maynooth University’s Department of Biology, working in the research group led by Prof Andrew Hogan at the Kathleen Lonsdale Institute for Human Health Research. It was carried out in collaboration with Prof Helen Heneghan and Prof Donal O’Shea at St Vincent’s University Hospital and University College Dublin, and was funded by the Health Research Board. Hogan said the results offer new insight into the relationship between obesity and immune dysfunction, while Prof Paul Moynagh described the project as an example of translational research connecting scientific and clinical expertise. Heneghan said the findings show that successful obesity treatment with RYGB was associated with reversal of the measured immune dysfunction.

Obesity is widely associated with increased risks of severe infection and other health complications, but identifying a biological mechanism is different from proving a clinical outcome. The Maynooth study suggests that altered energy metabolism in Vδ2+ T cells may be one factor connecting obesity with diminished immune readiness. It also shows that these measured cellular abnormalities can improve after bariatric surgery. Whether that recovery translates into fewer infections, better cancer outcomes, or durable immune benefits remains a separate question requiring appropriately designed clinical research.

Subject of Research: Effects of Roux-en-Y gastric bypass on obesity-associated defects in Vδ2+ T-cell metabolism and function

Article Title: Maynooth University research finds bariatric surgery can restore immune cell function affected by obesity

Article References: Maynooth University research finds bariatric surgery can restore immune cell function affected by obesity. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: obesity, bariatric surgery, immune cells, Vδ2+ T cells, cellular metabolism, gamma delta T cells, immune dysfunction, Roux-en-Y gastric bypass, cancer immunity, Maynooth University, Maynooth, University

Heterodimeric therapeutic proteins offer a way to engage multiple disease pathways with a single molecule, but their development has been hindered by the lack of rapid, quantitative assays capable of distinguishing homodimer impurities from the target heterodimer. When Fc-containing chains pair randomly, more than 90 percent of the product formed could be mispaired, so engineers have deployed knobs-into-holes steric designs, electrostatic steering, kappa-lambda light chain pairing, and engineered Protein A binding to promote and isolate heterodimers. Even with these strategies, the two halves of a bispecific molecule frequently share nearly identical molecular weight, isoelectric point, and hydrophobicity, leaving little resolving power for high-throughput purity analysis early in process development.

The molecule at the center of the study, termed BTN2A1/3A1-Fc-TAscFv, is a bispecific Fc fusion protein designed to activate Vγ9Vδ2 T cells and direct them to kill tumor cells. Each polypeptide chain consists of the extracellular domain of a butyrophilin protein, BTN2A1 or BTN3A1, linked via an Fc domain to a tumor antigen-specific single-chain antibody fragment. Because both chains are produced in the same cell line, the upstream bioprocess is expected to generate BTN2A1 and BTN3A1 homodimer impurities alongside the therapeutic heterodimer. The three species differ only slightly in predicted molecular weight, at 155.4, 154.9, and 155.1 kDa, and in predicted isoelectric point, at 8.4, 7.4, and 7.7, respectively.

The decisive difference lies in glycosylation. Based on sequence analysis, the BTN2A1 chain carries seven N-linked glycosylation sites while the BTN3A1 chain carries three, meaning the heterodimer contains ten sites, the BTN2A1 homodimer fourteen, and the BTN3A1 homodimer six. Prior research has shown that a single N-linked glycosylation site can increase a glycoprotein’s apparent molecular weight in sodium dodecyl sulfate capillary gel electrophoresis by up to 10 kDa, because carbohydrate moieties alter electrophoretic mobility through the sieving matrix. The team therefore predicted an apparent 40 kDa difference between the heterodimer and each homodimer, sufficient for baseline resolution on a platform routinely used to detect impurities differing by roughly 25 kDa.

Conventional platforms fell short. Size exclusion chromatography showed a retention time difference between the homodimers, but the theoretical USP resolution between the two peaks was only 0.34, inadequate for quantitative purity assessment. Matrix-assisted laser desorption/ionization mass spectrometry confirmed observed molecular weights of 175.7 and 160.8 kDa for the BTN2A1 and BTN3A1 homodimers, reflecting post-translational modifications, but the technique is non-quantitative and could not resolve the species in heterogeneous process samples. Imaged capillary isoelectric focusing revealed overlapping apparent isoelectric points, with the BTN2A1 homodimer profile spanning 7.4 to 8.1 and the BTN3A1 homodimer peaking at 7.7, ruling out charge-based separation.

Under reducing conditions, CE-SDS produced relative migration times of 1.85 and 2.04 for the BTN3A1 and BTN2A1 homodimer controls, and the heterodimer sample yielded two prominent peaks at 1.85 and 2.03, corresponding to the two constituent monomers. Under non-reducing conditions, the homodimer controls migrated at 2.35 and 2.62, while the heterodimer sample produced three peaks at 2.37, 2.48, and 2.60. The middle peak, designated Peak 2-NR, migrated between the two homodimers, exactly as expected if glycosylation were the primary separation mechanism, since the heterodimer carries an intermediate number of glycan sites.

To confirm the mechanism, the researchers digested samples with PNGase F to strip N-linked glycans. After deglycosylation, all three species collapsed to a single peak with identical relative migration times under both reducing and non-reducing conditions, demonstrating that the degree of glycosylation was the primary driver of peak separation. SDS-PAGE and Western blot analysis corroborated the findings. Under non-reducing conditions, the heterodimer sample produced three bands at approximately 193, 186, and 181 kDa, and dual-color Western blotting with BTN2A1-specific and BTN3A1-specific antibodies labeled the bands blue, teal, and green, respectively, confirming the presence of both homodimers and the heterodimeric species in the purified product.

The method proved directly useful for manufacturing. A three-step chromatography process, comprising affinity capture, mixed-mode intermediate purification, and ion exchange polishing, was developed to enrich for Peak 2-NR. Non-reduced CE-SDS showed Peak 2-NR content rising from 24.6 percent after capture to 76.7 percent after polishing. A dual-binding bio-layer interferometry assay, in which protein must be bound simultaneously by BTN2A1-specific and BTN3A1-specific antibodies to register as heterodimer, confirmed the enrichment, with the EC50 of the dose response curve falling from 18.6 μg/mL at capture to 7.5 μg/mL after polishing, a decrease nearly matching the purity gain measured by CE-SDS.

Method validation followed ICH criteria for linearity, repeatability, and accuracy across concentrations of 0.5 to 1.5 mg/mL. The coefficient of determination for the heterodimer species was 1.00, with homodimer values of 0.99 and 0.98. Repeatability, expressed as percent relative standard deviation of triplicate preparations, ranged from 2 to 9 percent across all concentrations and species, and percent recovery ranged from 93 to 111 percent. These performance characteristics support the use of CE-SDS for GMP-compliant batch release and stability testing in quality control, not merely for development-stage characterization.

The broader implication is that glycosylation asymmetry can serve as an analytical handle where size, charge, and hydrophobicity fail. The authors note the approach can be extended to other bispecifics and fusion proteins provided sufficient glycosylation differences exist between the constituent chains, and conceivably, one half of a molecule could be engineered to carry additional N-glycan sites to enable separation, analogous to isoelectric point engineering. By adding glycosylation site count to the list of separable quality attributes, the method expands the analytical toolkit for heterodimer purity determination in a class of therapeutics whose structural similarity has long obscured impurity detection.

Subject of Research: Analytical method development using capillary gel electrophoresis to determine heterodimer purity in a bispecific Fc fusion protein based on glycosylation differences

Article Title: Capillary gel electrophoresis for the analysis of heterodimer purity in a highly glycosylated, bispecific Fc fusion protein

Article References: Daniels, C., Jones, K., Makani, V., Schmidt, C., Pate, J., Wu, D., Schreiber, T. H., De Silva, S., Shukla, A., & Oien, N. (2026). Capillary gel electrophoresis for the analysis of heterodimer purity in a highly glycosylated, bispecific Fc fusion protein. Frontiers in Analytical Science, 6, Article 1739382. https://doi.org/10.3389/frans.2026.1739382

Image Credits: AI Generated

DOI: 10.3389/frans.2026.1739382

Keywords: capillary gel electrophoresis, CE-SDS, bispecific protein, Fc fusion protein, heterodimer purity, glycosylation, N-linked glycans, biopharmaceutical analysis, method validation, quality control, butyrophilin, gamma delta T cells

The central problem that has stymied treatment efforts for decades is invisibility. Immunotherapy, which has revolutionised outcomes in melanoma and other cancers, works primarily by unleashing conventional immune cells, most notably alpha beta T cells, to attack tumours. But small cell lung cancer is exceptionally adept at hiding from these standard immune defenders. The tumours present few of the molecular flags that conventional T cells need to identify a target, and only a rare subset of patients derives long-term benefit from checkpoint inhibitor drugs. This immune invisibility is a major reason why advances in small cell lung cancer treatment have been so scarce, and why the disease has seen few meaningful therapeutic improvements over the past several decades.

Gamma delta T cells offer a fundamentally different route of attack. Unlike their alpha beta counterparts, these cells recognise targets through distinct sensing mechanisms that do not depend on the usual antigen-presenting machinery, allowing them to detect stressed or transformed cells through patterns that tumours find harder to conceal. The WEHI team, led by senior author Professor Kate Sutherland, found that patients whose tumours contained higher levels of gamma delta T cells tended to live longer, a correlation that suggests these cells constitute a genuine, functional line of anti-cancer defence rather than a passive presence. In tissue samples taken from long-term survivors, the researchers could see gamma delta T cells infiltrating the tumour, in direct contact with the cancer cells they appeared to be attacking.

To test this potential rigorously, the team turned to an innovative laboratory platform: miniature tumours, or organoids, grown from patient-donated samples. These samples were provided through the Victorian Cancer Biobank in collaboration with the Royal Melbourne Hospital, and the resulting mini tumours represent one of the most realistic laboratory models of small cell lung cancer developed to date. Because they preserve the cellular and molecular complexity of the original patient tumours, they offer a far more faithful testing ground than traditional two-dimensional cell cultures. When the researchers combined these mini tumours with gamma delta T cells harvested from the same patients’ blood, the immune cells proved highly effective at recognising and killing the SCLC cells, even when the disease had adopted its usual camouflage.

Perhaps the most clinically exciting discovery is that the cancer-killing activity of these cells can be amplified using drugs that already exist. The team identified two approved therapies that, in combination, dramatically strengthened the gamma delta T cell response. The first, zoledronate, is a bisphosphonate already approved for osteoporosis and cancer-related bone disease. In the study, zoledronate increased the number of gamma delta T cells available and enhanced their ability to recognise the tumours. The second, tarlatamab, is a bispecific antibody recently approved as a cancer treatment for small cell lung cancer itself. Tarlatamab acted, in the researchers’ description, like a magnetic force, physically drawing the immune cells into closer contact with the cancer cells so that the killing could proceed efficiently.

The synergy between these two agents points toward a rational combination strategy. Zoledronate effectively primes and expands the gamma delta T cell population, while tarlatamab bridges the gap between immune cell and tumour, ensuring that the activated killers reach their targets. Together, the drugs significantly enhanced the ability of gamma delta T cells to attack cancer cells in the laboratory models. Because both drugs are already approved for human use, albeit for different indications, the path from laboratory finding to clinical testing could be considerably shorter than for an entirely novel therapy. This repurposing opportunity is what gives the discovery its immediate translational appeal.

Dr Jin Ng, first author on the paper, highlighted another promising dimension: adoptive cell transfer. This approach, already proven with CAR-T therapies in blood cancers, involves collecting a patient’s immune cells, growing them to large numbers outside the body, and infusing them back into the patient. As Ng noted, therapies that expand and reinfuse gamma delta T cells already exist, raising the possibility of rapidly translating the current findings into new treatment strategies. For patients whose tumours contain low levels of gamma delta T cells, drugs such as zoledronate might first boost their native population of cancer-fighting cells, improving their responsiveness to existing treatments. The researchers suggest this could open an entirely new avenue for personalised treatment approaches, not only in small cell lung cancer but potentially in other solid cancers that evade conventional immune surveillance.

A crucial part of the evidence base came from an unexpected source: landmark clinical trials. Rather than starting from scratch, the team analysed data from IMpower133 and CASPIAN, the two practice-changing trials that established immunotherapy as a standard of care for small cell lung cancer. Using advanced genomic and computational analyses conducted by WEHI’s genomics and bioinformatics teams, the researchers searched for immune signatures associated with exceptional treatment responses. What emerged was a clear pattern: patients who experienced the greatest benefit from immunotherapy carried a strong gamma delta T cell signature in their tumours. This retrospective human evidence, combined with the functional organoid experiments, forms a compelling two-pronged case that these cells matter clinically, not merely in theory.

The implications extend beyond a single cancer type. Small cell lung cancer is a neuroendocrine malignancy characterised by rapid growth, early metastasis, and a tumour microenvironment that suppresses conventional immunity. If gamma delta T cells can see through that suppression, the same logic may apply to other tumours that are similarly invisible to standard immunotherapy, a category that includes many of the hardest-to-treat solid cancers. The WEHI team, working in an ongoing collaboration with researchers at the Doherty Institute, now hopes to translate the findings into a new class of immunotherapy drugs for small cell lung cancer. The research was supported by Cancer Council Victoria, the National Health and Medical Research Council, The CASS Foundation, and the International Association for the Study of Lung Cancer.

For a disease that has remained stubbornly resistant to progress, the study offers something rare: a concrete, testable mechanism that connects immune biology to patient survival and points to drugs that are already on pharmacy shelves. Much work remains before gamma delta T cell-based strategies reach the clinic, including formal clinical trials to establish safety and efficacy in small cell lung cancer patients. But the convergence of patient-derived organoid data, clinical trial evidence, and repurposable approved drugs gives this discovery a momentum that few laboratory findings achieve. After decades in which small cell lung cancer successfully hid from the immune system and from therapeutic innovation alike, one of its most effective disguises may finally have been seen through.

Subject of Research: Gamma delta T cell immunity and drug-enhanced immunotherapy for small cell lung cancer

Article Title: Invisible no more: New treatment avenue unlocked for deadliest lung cancer

Article References: Invisible no more: New treatment avenue unlocked for deadliest lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: small cell lung cancer, gamma delta T cells, immunotherapy, organoids, zoledronate, tarlatamab, cancer immunology, WEHI, Cancer Cell, adoptive cell therapy, tumour immune evasion, drug repurposing

Vδ1 T cells belong to the gamma-delta T cell family, a small subset of lymphocytes that carry an unconventional T cell receptor built from delta and gamma chains rather than the familiar alpha and beta chains found on most T cells. What makes them attractive for cancer immunotherapy is their recognition strategy. Unlike conventional T cells, which scan cells for peptide fragments presented on major histocompatibility complex molecules, Vδ1 T cells detect stress-associated ligands and other danger signals that appear on the surface of transformed and infected cells. This MHC-independent recognition means that donor-derived Vδ1 T cells can, in principle, be infused into unrelated recipients without the severe rejection risks and graft-versus-host complications that complicate other allogeneic cell therapies. Their natural tendency to home into tissues adds a further advantage for attacking solid tumors, which are notoriously difficult for circulating immune cells to infiltrate.

Yet the same rarity that makes Vδ1 T cells immunologically convenient also makes them logistically challenging. They typically account for only a small fraction of the lymphocytes circulating in peripheral blood, so isolating enough of them for manufacturing has been a persistent obstacle. The research team, led by Shuntian Chen, Lujie Zhao, Xinrui Xie, Haoyuan Wu and senior author Hongling Wu, with institutions including the Guangzhou Institute of Respiratory Health at Guangzhou Medical University and the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences, set out to determine whether IL-18, a cytokine already known to shape the behavior of conventional T cells and natural killer cells, could unlock the proliferative potential of Vδ1 T cells as well.

The experimental design was straightforward but systematic. The researchers isolated primary human Vδ1 T cells from donor blood using magnetic bead separation and cultured them with antibodies against CD3, a coreceptor that provides T cells with an activation signal, together with interleukin-15, a growth factor widely used to drive the expansion of innate-like lymphocytes. Some cultures received IL-18 in addition; others did not. The team then tracked how fast the cells divided, what surface molecules they displayed, and how long they survived, using flow cytometry to quantify each of these parameters across the culture period.

The results on proliferation were striking. IL-18 significantly accelerated cell-cycle progression, pushing the Vδ1 T cells into division more rapidly and sustaining robust clonal expansion over the course of the culture. Crucially, this growth did not come at the cost of purity: the expanded populations retained a high proportion of genuine Vδ1 T cells, an important consideration for any manufacturing process in which overgrowth of contaminating cell types can render a product unusable. For a cell type whose scarcity has been the primary barrier to clinical translation, the ability to generate large, clean batches from a modest starting population represents a substantial advance in manufacturability.

Expansion alone, however, is not enough. Cells grown in the laboratory must remain functional when they encounter the hostile environment of a tumor, where nutrient deprivation, hypoxia and immunosuppressive signals conspire to exhaust or kill infiltrating lymphocytes. Here too, IL-18 left a measurable imprint. The cytokine-treated Vδ1 T cells showed enhanced survival during prolonged exposure to tumor cells, suggesting that IL-18 conditioning confers a degree of resistance to the apoptotic pressures of the tumor microenvironment. They also produced greater quantities of inflammatory cytokines, including interferon-gamma and tumor necrosis factor alpha, which can recruit and activate other arms of the immune response, and they migrated more effectively toward tumor-derived signals in directed migration assays.

One result complicates the otherwise rosy picture and reveals something important about how IL-18 reshapes these cells. In short-term laboratory killing assays, the IL-18-expanded Vδ1 T cells actually showed reduced contact-dependent cytotoxicity, meaning they were somewhat less efficient at directly killing tumor cells through cell-to-cell contact. This apparent deficit, however, did not translate into weaker antitumor activity in living animals. The researchers turned to RNA sequencing and quantitative PCR to probe the transcriptional shifts underlying these changes, finding alterations in gene programs associated with cell survival, inflammatory signaling and apoptosis regulation, including changes in genes such as BAX, a pro-apoptotic regulator, and death receptor pathway components. The molecular profile suggested that IL-18 redirects the cells away from a purely cytotoxic specialization and toward a more durable, inflammation-oriented and tissue-infiltrating state.

The decisive test came in an animal model. The team used mice bearing xenografts of A549 cells, a human lung carcinoma line derived from a non-small cell lung cancer, and compared the therapeutic effects of IL-18-conditioned Vδ1 T cells against control Vδ1 T cells expanded without the cytokine. Bioluminescence imaging was used to track tumor burden over time. The IL-18-expanded cells suppressed tumor growth more effectively and, most importantly, significantly prolonged the survival of the tumor-bearing mice. The in vivo superiority of the IL-18-conditioned product, despite its reduced immediate killing capacity in vitro, underscores a recurring lesson in cell therapy development: laboratory killing assays do not always predict therapeutic performance, and properties such as persistence, migration and cytokine output can matter more for solid tumor control than raw cytotoxicity measured over a few hours in a culture dish.

The translational implications are considerable. Because Vδ1 T cells can be used in an allogeneic, off-the-shelf format, an optimized expansion protocol could enable the production of standardized cell products from healthy donors, manufactured in advance and administered to many patients without the individualized engineering timelines required for autologous therapies such as CAR-T cells. The study also did not involve clinical research on human subjects; all animal work was approved by the Institutional Animal Care and Use Committee of the Guangzhou Institutes of Biomedicine and Health, and the findings remain at the preclinical stage. Moving from xenograft models to human trials will require demonstrating safety, dosing feasibility and efficacy in patients, and the authors note that the work was supported by the National Natural Science Foundation of China and the National Key Research and Development Program of China.

For the broader field of gamma-delta T cell immunotherapy, the study adds IL-18 to the toolkit of cytokines that can be deployed to tune cell products for specific therapeutic goals. Interleukin-15 has long served as the workhorse expansion factor for innate-like lymphocytes, but IL-18 appears to impart a complementary identity, one that favors longevity, inflammatory potency and tumor homing over immediate cytolytic function. As researchers continue to engineer gamma-delta T cells with chimeric antigen receptors and other enhancements, the ability to shape their baseline fitness through cytokine conditioning could prove essential. If the results hold up in clinical testing, a simple change to the culture recipe, the addition of a single signaling molecule, may help transform a scarce circulating curiosity into a scalable weapon against some of the hardest tumors to treat.

Subject of Research: IL-18-driven expansion and functional enhancement of human Vδ1 gamma-delta T cells for solid tumor immunotherapy

Article Title: IL‑18 improves the expansion and functional fitness of human Vδ1 T cells for superior solid tumor immunotherapy

Article References: Chen, S., Zhao, L., Xie, X., Wu, H., Hu, S., Han, X., Li, T., Chen, J., & Wu, H. (2026). IL‑18 improves the expansion and functional fitness of human Vδ1 T cells for superior solid tumor immunotherapy. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09079-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09079-w

Keywords: Vδ1 T cells, gamma-delta T cells, IL-18, interleukin-15, immunotherapy, solid tumors, lung cancer, adoptive cell therapy, cytokines, tumor microenvironment, allogeneic cell therapy, preclinical study

The focus of the new work is a population of immune cells known as gamma delta T cells, a specialist lineage that patrols tissues throughout the body, including the skin and the gut, on the lookout for damage, infection and cancer. Unlike the more familiar alpha beta T cells that dominate adaptive immunity, gamma delta T cells have long been regarded as immunological hybrids. They can detect signs of cellular stress and dysregulation without needing the lengthy priming that conventional adaptive responses require, and they can act rapidly against abnormal cells. That combination of speed and broad reactivity has made them one of the most promising candidates for next-generation cancer immunotherapies, and scores of clinical trials are currently underway to harness their potential.

Yet a fundamental question has lingered beneath all of that clinical enthusiasm. Like other adaptive immune cells, gamma delta T cells carry signature receptors on their surface, the products of the same genetic rearrangement machinery that generates the vast receptor repertoires of conventional T and B cells. During development, these so-called T cell receptors help shape how gamma delta T cells mature, where they settle in the body and how prepared they are to respond to particular kinds of stress. But many researchers had assumed that once the cells were mature and deployed into tissues, the receptor’s job was essentially done. If gamma delta T cells respond so rapidly and so innately, surely their adaptive receptor could not be involved in real time?

Adrian Hayday, Principal Group Leader at the Francis Crick Institute who has studied gamma delta T cells for more than four decades, teamed up with Miguel Munoz-Ruiz, a former postdoc in his laboratory who now leads his own research programme at Complutense University of Madrid, to answer that question definitively. “There is a lot of interest and progress in using gamma delta T cells in cancer immunotherapies, or even other types of immune treatment, because they can recognise any kind of dysregulation and act quickly,” Hayday explains. “But if we are going to use them clinically, we need to understand what underpins that rapid response.”

The two teams designed a series of experiments to ask what happens when the gamma delta T cell receptor is removed from mature cells that are already stationed in tissues. In mice engineered so that the receptor could be deleted from selected populations of resident gamma delta T cells, the researchers, working with Nicolas Veland in Hayday’s lab and Bethania Garcia-Cassani in Munoz-Ruiz’s team, observed that the receptor was essential to the cells’ continuing tissue surveillance function. This was a striking result. The cells did not simply carry on with their innate-like patrol work once the receptor was gone; instead, their core identity as sentinels began to unravel.

When the receptor was removed, the gamma delta T cells remained physically present in the tissues, but their behaviour changed markedly. The researchers documented alterations in the activity of genes involved in activation, tissue surveillance and communication with other immune cells. Perhaps most tellingly, they also saw disruption to receptors associated with innate immune responses, the very molecular machinery that was supposed to operate independently of adaptive recognition. In other words, pulling out the adaptive receptor did not leave the innate program intact; it compromised it.

To determine whether the same principle holds in human cells, Veland undertook key parts of the experimental work in laboratory-grown human gamma delta T cells, using CRISPR gene-editing technology to disrupt a gene encoding part of the gamma delta T cell receptor. The result echoed the mouse findings closely. Removing the receptor altered gene activity and reduced the expression of several receptors associated with innate responses, indicating that the dependence on receptor signalling is not a quirk of the mouse immune system but a conserved feature of gamma delta T cell biology across species.

The consequences for cancer surveillance were equally significant. Across mouse models of both skin cancer and colorectal cancer, the loss of the gamma delta T cell receptor impaired the immune system’s ability to control tumour development. In further laboratory experiments, receptor-deficient human gamma delta T cells were less able to restrict the growth of melanoma and colorectal cancer cells. Taken together, these results demonstrate that the rapid, innate-like anti-tumour activity that makes gamma delta T cells so attractive for immunotherapy is not a receptor-independent property of the cells themselves; it depends, in real time, on the continuous signalling of their adaptive T cell receptor.

“This work came from a shared question that Adrian and I kept coming back to,” says Munoz-Ruiz. “If gamma delta T cells are so rapid and so innate-like, what is their receptor doing?” The answer, the teams have now shown, is that the receptor is doing a great deal. “We’ve shown that without receptor signalling, gamma delta T cells are much less able to carry out rapid tissue surveillance, showing that responses previously thought to be independent of adaptive immune recognition still rely on the gamma delta T cell receptor in real time.” The finding reframes the receptor not as a developmental scaffold that can be discarded after maturation, but as an ongoing operational requirement for the cells’ frontline duties.

For the growing field of gamma delta T cell therapy, the implications are immediate and practical. The findings suggest that gamma delta T cell treatments may depend on preserving or activating the receptor signal that helps these cells recognise and respond to damage and disease. Therapeutic strategies that expand or transfer gamma delta T cells without safeguarding their receptor function could, according to this new evidence, deliver cells that are present but functionally blunted. “These findings are incredibly important if we want those cells to attack tumours effectively,” Hayday adds. Beyond the clinic, the study points to what the researchers describe as a fundamental shift in how immune responses are understood. These cells defy the traditional classifications of immunity: an adaptive receptor being used as part of the innate immune response. That may, Hayday suggests, explain why gamma delta T cells have been conserved across many different species, offering an essential and unique form of surveillance that does not fit neatly into either category of the classical immune dichotomy.

Subject of Research: The role of gamma delta T cell receptors in rapid innate-like tissue surveillance and cancer immunosurveillance

Article Title: Immune cells defy textbook classifications

Article References: Immune cells defy textbook classifications. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gamma delta T cells, innate immunity, adaptive immunity, T cell receptor, cancer immunotherapy, tissue surveillance, Francis Crick Institute, Nature, CRISPR, tumour immunology, immune cell receptors, immunosurveillance

Gamma delta T cells occupy a curious middle ground in immunology. Unlike their alpha-beta cousins, which recognize peptide fragments presented by major histocompatibility molecules, gamma delta T cells can respond to phosphoantigens, small metabolite-like molecules that accumulate in stressed and transformed cells. This unconventional recognition has made them attractive targets for cancer immunotherapy, and clinical efforts to expand and harness them are underway worldwide. But if gamma delta T cells are to be deployed rationally in the clinic, researchers need to know which checkpoint receptors they carry, when those receptors appear, and what they actually mean for cell function. The new work addresses precisely this gap, and its central message is that checkpoint expression on gamma delta T cells is governed by receptor identity, T-cell lineage, and environmental context all at once.

The experimental design combined laboratory manipulation of living cells with computational mining of published single-cell datasets. The team isolated peripheral blood mononuclear cells from healthy donors and stimulated them in vitro under different conditions, then used flow cytometry to track how checkpoint receptor expression changed over time on both gamma delta and alpha-beta T-cell subsets. In parallel, they reanalyzed previously published single-cell RNA-sequencing data from tumor-infiltrating gamma delta and CD8 T cells, looking for how checkpoint expression was distributed across differentiation states and how it shifted in patients who had received immune checkpoint blockade therapy. This dual approach allowed the researchers to connect what happens in a culture dish with what happens inside human tumors.

The first major finding concerned how different modes of stimulation produce different checkpoint profiles. When the researchers applied polyclonal stimulation, a blunt activation signal that drives many T cells at once, they observed a broad upregulation of checkpoint receptors across the board. But when they expanded V delta 2 T cells, the dominant gamma delta subset in human blood, using phosphoantigen-driven activation, the resulting profile was far more selective. TIM-3 expression rose and remained sustained, while PD-1 and TIGIT showed only transient modulation. In other words, the way a gamma delta T cell is activated leaves a lasting imprint on which brakes it carries, a detail that could matter enormously for clinical protocols that expand these cells ex vivo before infusion into patients.

The second key insight came from mapping checkpoint receptors onto the differentiation journey of T cells. T cells progress through recognizable stages, from naive cells that have never met their antigen, through central memory and effector memory populations, to terminally differentiated effector memory cells. The researchers found that checkpoint distribution was structured along this trajectory, but not in a uniform way. TIGIT was enriched in antigen-experienced subsets, consistent with its association with repeated antigen encounter. LAG-3 and TIM-3, by contrast, were concentrated in naive compartments, an unexpected pattern that challenges the assumption that these receptors simply mark worn-out cells. PD-1 was expressed broadly, appearing across multiple differentiation states rather than clustering at any single stage.

These distribution patterns carry a pointed implication: checkpoint receptor expression alone cannot be used as a proxy for T-cell exhaustion. In alpha-beta T-cell biology, high PD-1 expression is often read as a sign of a dysfunctional, exhausted state that checkpoint blockade can rescue. But the Palermo team’s data show that gamma delta T cells can display checkpoint receptors as a normal feature of activation and differentiation, without any evidence of functional collapse. The authors are careful on this point, noting that because classical exhaustion-associated transcriptional and epigenetic programs were not evaluated in their study, the observed patterns neither establish nor exclude the presence of exhausted gamma delta T-cell subsets. What the data do establish is that checkpoint expression is dynamically shaped by activation history, differentiation state, and environmental context, making single-marker interpretations unreliable.

Functionally, the team tested what happens when the brakes are released. Blocking PD-1 produced donor-dependent trends toward increased proliferation and cytokine production, an effect that was particularly noticeable when the cells were cultured with interleukin-15, a cytokine known to support gamma delta T-cell survival and cytotoxicity. The donor-to-donor variability is itself informative, suggesting that the responsiveness of a patient’s gamma delta T cells to checkpoint blockade may depend on their individual immune baseline. TIM-3 inhibition, meanwhile, showed variable effects across experiments, and combining PD-1 and TIM-3 blockade did not produce a consistent additive response. For a field increasingly interested in combination checkpoint therapies, this absence of synergy in gamma delta T cells is a caution against assuming that strategies validated in alpha-beta biology will transfer cleanly.

The single-cell transcriptomic analysis added a tumor-side perspective. When the researchers examined tumor-infiltrating gamma delta T cells from published datasets, they found heterogeneous checkpoint expression scattered across differentiation states, with no single coherent pattern. CD8 alpha-beta T cells from the same tumors, in comparison, showed a more progressive, stepwise accumulation of checkpoint expression as they differentiated. This lineage-specific architecture suggests that gamma delta T cells inside tumors do not follow the same trajectory of escalating checkpoint burden that characterizes conventional cytotoxic T cells. Intriguingly, the analysis of samples from patients who had undergone immune checkpoint blockade therapy revealed that alternative checkpoint receptors tended to persist or even increase after treatment, hinting at compensatory mechanisms that could blunt therapeutic responses.

The translational stakes of this work are considerable. Gamma delta T cells are being pursued as cellular therapies for cancer, and several approaches involve expanding V delta 2 T cells with aminobisphosphonates such as zoledronic acid, which causes phosphoantigen accumulation in target cells. The finding that phosphoantigen-driven expansion produces a distinctive checkpoint signature, with sustained TIM-3 and only transient PD-1 modulation, gives therapy developers a molecular fingerprint to monitor and potentially manipulate. If the checkpoint profile of an infused gamma delta product determines how long it survives and functions in a patient, then tuning the expansion conditions becomes a rational design parameter rather than an afterthought. Similarly, the donor-dependent response to PD-1 blockade under interleukin-15 stimulation suggests that biomarker-guided patient selection could improve the odds of combination regimens involving gamma delta cells.

Beyond the immediate clinical implications, the study is a reminder that immunology’s most influential paradigms are built on a fraction of the immune system’s diversity. Checkpoint receptors are not a single switch with a single meaning; they are a family of regulatory molecules whose expression and function depend on which T-cell lineage carries them, how that cell was activated, and where it finds itself. For gamma delta T cells, the brakes may be part of the normal operating machinery rather than a sign of breakdown. Disentangling genuine exhaustion from routine checkpoint expression will require integrating receptor measurements with transcriptional and epigenetic profiling, work that the authors flag as the necessary next step. As gamma delta T-cell therapies move closer to the clinic, studies like this one provide the context-dependent framework that careful translation demands, ensuring that the next generation of immunotherapies is designed around how these unconventional cells actually behave.

Subject of Research: Immune checkpoint receptor dynamics in human gamma delta T cells

Article Title: Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells

Article References: Corsale, A. M., Di Simone, M., Cerapio, J. P., Lo Presti, E., Pizzolato, G., Avellone, C., Dieli, C., Marchiafava, S., Di Paola, L., Dieli, F., & Meraviglia, S. (2026). Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09004-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09004-1

Keywords: gamma delta T cells, immune checkpoint receptors, immune checkpoint blockade, T-cell exhaustion, PD-1, TIM-3, TIGIT, LAG-3, single-cell RNA sequencing, cancer immunotherapy, Vdelta2 T cells, flow cytometry

Attenuated sporozoites, the infective stage of Plasmodium parasites injected by mosquitoes, have been tested as vaccines for decades because they provoke robust adaptive immunity that protects against subsequent challenge. The most advanced of these approaches, whole-sporozoite vaccines designed to protect through hepatic CD8 T cell immunity, have shown encouraging results in clinical trials. Yet a fundamental question has lingered: how do these parasites engage the innate immune system to license such potent T cell responses? Pattern recognition receptors such as Toll-like receptors and inflammasome sensors are the canonical gatekeepers of innate immunity, but their role in sporozoite immunogenicity has never been clearly defined.

To answer this, the team built what they describe as a reductionist system. They generated fluorescent GFP-expressing Plasmodium berghei and Plasmodium falciparum sporozoites, purified the parasites by flow cytometry directly from mosquito salivary glands, and sorted them onto mouse bone marrow-derived macrophages or human peripheral blood mononuclear cells. This allowed them to isolate the innate response to sporozoites from the confounding signals of mosquito saliva, blood-stage parasites, and other contaminants that complicate whole-organism studies. They then profiled the responding cells using bulk and single-cell RNA sequencing, capturing the transcriptional landscape of innate activation at high resolution.

The results were striking. Sporozoites did not induce the classical inflammatory programs associated with microbial pattern recognition. Instead, the transcriptional signature in macrophages and human monocytes resembled a cell wounding response, the program that cells mount when their plasma membrane is breached. This makes biological sense: sporozoites must traverse host cells as they migrate from the skin through the dermis to the liver, breaching the membranes of the cells they pass through before finally settling in hepatocytes. The parasites, in effect, leave a trail of wounded cells, and the immune system reads that trail as a danger signal.

The evidence for this interpretation came from a decisive genetic experiment. The researchers used sporozoites lacking SPECT1, a protein with a membrane attack complex-like domain that is essential for pore formation and cell traversal. These traversal-deficient parasites, which can still invade hepatocytes but cannot punch through intermediate cells, failed to activate bone marrow-derived macrophages in vitro. The wounding signature disappeared entirely when the pore-forming machinery was removed, demonstrating that the innate activation was not triggered by parasite molecules detected by conventional sensors but by the physical damage the parasite inflicts on host cells.

Importantly, the wounding response was independent of both inflammasome and Toll-like receptor signalling, the two most intensively studied pathways of innate immune activation. This rules out the standard explanation and points instead toward a distinct sensing modality. Previous work from other laboratories has shown that cells surviving sublethal plasma membrane injury mount a characteristic transcriptional response involving repair machinery and chemokine production, and the sporozoite-induced signature overlapped with these curated plasma membrane injury gene sets. The immune system, it appears, can detect the wound itself rather than the weapon that caused it.

The study then connected this innate sensing to the adaptive immunity that actually protects against malaria. In mice immunized with traversal-deficient irradiated sporozoites, the priming of protective CD8 T cell responses was markedly impaired compared with immunization using normal traversal-competent parasites. Given that CD8 T cells are the critical mediators of sterile immunity against the liver stage of malaria, this deficit is not a minor detail. It suggests that the wounding of host cells during traversal is not incidental damage but an essential adjuvant-like signal that the whole-sporozoite vaccine platform depends upon.

A further layer of the mechanism involves γδ T cells, an unconventional lymphocyte population that bridges innate and adaptive immunity. The researchers found that the sensing of cell traversal required γδ T cells, which are already known to support CD8 T cell responses against Plasmodium. Earlier work has shown that γδ T cells are required for the induction of sterile immunity during irradiated sporozoite vaccination, and recent studies have demonstrated that γδ T cell-derived IL-4 can initiate CD8 T cell immunity. The new findings place these cells squarely within the sensing pathway: they appear to translate the cell wounding signal into help for the CD8 T cells that will later eliminate infected hepatocytes.

The cross-species consistency of the results strengthens their significance. Human monocytes exposed to Plasmodium falciparum sporozoites showed an activation pattern that overlapped with the mouse data, including the plasma membrane injury signature, indicating that the mechanism is not a rodent-specific curiosity but likely operates in human malaria infection and vaccination. Single-cell RNA sequencing of human peripheral blood mononuclear cells revealed that multiple innate cell types respond to sporozoites, with the response distinguishable from that induced by blood-stage parasites, which instead triggered more conventional inflammatory programs.

For vaccine development, the implications are considerable. Subunit vaccines based on the circumsporozoite protein have struggled to achieve the high levels of protection seen with whole sporozoites, and this study offers a possible explanation: they lack the cell traversal signal that recruits γδ T cells and licenses potent CD8 T cell priming. Incorporating a wounding-mimetic adjuvant, or designing vaccine delivery strategies that reproduce the membrane injury signal, could help close that gap. Conversely, the findings caution that any attenuated sporozoite vaccine engineered to block traversal, however attractive from a safety standpoint, might sacrifice immunogenicity. As malaria continues to claim hundreds of thousands of lives each year, understanding why live sporozoites are such effective teachers of the immune system brings the field one step closer to a vaccine that can match that performance without a live parasite.

Subject of Research: Innate immune sensing of Plasmodium sporozoite cell traversal and its role in priming protective CD8 T cell responses

Article Title: Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses

Article References: Pohl, K. G., Gao, X., McGowan, J., Mukherjee, P., Le, S., Carreira, P., Ngo, C., Sutton, H. J., Brumhard, S., Hiller, A., Kelly, H. G., Liow, L., Lo, A., Henze, L., Loyal, L., Amino, R., Man, S. M., Beattie, L., Sander, L. E., & Cockburn, I. A. (2026). Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses. Nature Microbiology. https://doi.org/10.1038/s41564-026-02460-x

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02460-x

Keywords: malaria, Plasmodium, sporozoites, cell traversal, innate immunity, CD8 T cells, gamma delta T cells, vaccines, plasma membrane injury, Nature Microbiology, immunology, parasitology

A team led by Jeng-Rong Lin, Lakshay Kapil, Huan-An Tsai, Wen-Chieh Liao, Yu-Cheng Chou and senior author Chiung-Hui Liu of National Chung Hsing University and collaborating hospitals in Taiwan published the review in the journal Cancer Immunology, Immunotherapy on 24 September 2026. Their central argument is that two intertwined problems have held gamma-delta T cell therapies back: the intrinsic biological heterogeneity of the cells themselves, and the stress inflicted on them during laboratory manufacturing. By integrating recent advances in developmental biology, immune aging and cellular manufacturing, the authors propose a framework that could reshape how these therapies are designed, produced and deployed.

The first pillar of the review is developmental. Human gamma-delta T cells are not a single uniform entity but a layered family of subsets that emerge at different stages of life. Some lineages are seeded early in fetal development and persist for decades with tissue-homing and regulatory properties, while others are generated throughout life in response to infections and retain more pronounced inflammatory effector functions. This developmental layering means that the circulating gamma-delta T cell pool in a teenager looks fundamentally different from that of an eighty-year-old, not merely in proportion but in functional character. For a therapy that depends on harvesting, expanding and reinfusing a patient’s own cells, or on selecting donor cells for off-the-shelf products, that starting composition matters enormously.

To probe how aging reshapes these cells, the authors went beyond literature synthesis and re-analyzed publicly available single-cell RNA sequencing datasets of peripheral gamma-delta T cells from individuals spanning adolescence to old age. The analysis revealed an age-associated transcriptional remodeling program centered on mitochondrial dysfunction, oxidative stress and altered iron metabolism pathways. In practical terms, older donors’ gamma-delta T cells show molecular signatures consistent with reduced energy production capacity and heightened cellular stress, features that echo the broader phenomenon of immunosenescence. These findings suggest that donor age and cumulative immune history may directly influence the fitness of the cellular starting material used for adoptive therapies, a variable that most current clinical protocols do not systematically account for.

The second pillar of the review addresses what happens to these cells once they leave the body. Manufacturing gamma-delta T cell products typically requires ex vivo expansion, in which cells are stimulated with activating antibodies or bisphosphonate-based drugs and bathed in cytokine cocktails to drive them to multiply from millions to billions of copies. The review highlights a growing body of evidence that this process is far from benign. Repeated stimulation and prolonged culture push the cells toward terminal differentiation, exhaustion and senescence-like phenotypes. Cells that emerge from extended culture may look abundant under the microscope yet behave poorly once reinfused, showing shortened in vivo persistence, blunted cytotoxic activity and diminished capacity to home to tumors.

This manufacturing paradox helps explain a frustrating pattern in clinical data. Gamma-delta T cell therapies have consistently demonstrated strong safety profiles across numerous early-phase trials, with little of the cytokine release toxicity or graft-versus-host risk seen with other cell therapies. But objective response rates, especially in solid tumors, have lagged behind expectations. The review suggests that part of the answer lies in the product itself: infusions dominated by exhausted or senescent cells may simply lack the staying power and killing capacity needed to dent bulky, immunosuppressive tumors, no matter how impressive their performance in a laboratory dish.

Fortunately, the authors argue, the field is not short of potential solutions. They survey a range of emerging approaches aimed at preserving cellular fitness during manufacturing. Cytokine optimization involves tailoring the growth factors used in culture, favoring combinations that maintain a less-differentiated, more proliferative state rather than pushing cells toward terminal effector fates. Metabolic modulation seeks to bolster mitochondrial health and counteract oxidative stress, potentially through nutrient manipulation or pharmacological agents that support energy metabolism. Genetic engineering, including chimeric antigen receptor designs adapted for gamma-delta T cells, offers ways to enhance tumor recognition and resistance to the immunosuppressive tumor microenvironment.

Perhaps the most provocative strategy discussed is the use of senolytic interventions, drugs that selectively eliminate senescent cells. The review specifically references dasatinib, a tyrosine kinase inhibitor with known senolytic activity, as a candidate for purging dysfunctional cells from expanding cultures. By removing the senescent fraction during manufacturing, producers could in principle deliver products enriched for the most vigorous, persistent cells. The authors also emphasize that aging-informed donor selection, guided by the transcriptional markers their re-analysis uncovered, could help clinicians choose starting material with the greatest therapeutic potential, whether from young allogeneic donors or from patients whose own cells have aged more gracefully.

The review’s synthesis carries implications well beyond one cell type. It frames adoptive cell therapy not merely as a question of engineering smarter receptors but as a problem of cellular physiology, in which the biological age and stress history of the product determine clinical performance. As allogeneic, off-the-shelf gamma-delta T cell products move toward commercialization, understanding how developmental origin and donor age shape product quality could become a decisive competitive and scientific advantage. The authors call for integrating gamma-delta T cell developmental biology directly into manufacturing protocols, so that expansion conditions are designed around the biology of the specific subsets being grown rather than around one-size-fits-all stimulation recipes.

For patients with solid tumors, who still have limited options beyond surgery, radiation and checkpoint inhibitors, the promise of gamma-delta T cell therapy remains real but conditional. The Taiwanese team’s analysis makes clear that the path forward runs through the unglamorous details of cell culture: how long the cells are grown, what they are fed, how stressed they become, and how old they were to begin with. If the field can master those variables, the immune system’s most versatile tumor hunters may finally deliver on the expectations that two decades of research have built around them.

Subject of Research: Developmental biology and ex vivo manufacturing of human circulating gamma-delta T cells for adoptive cancer immunotherapy

Article Title: Revisiting human circulating γδ T cells: developmental insights and manufacturing challenges for cancer immunotherapy

Article References: Lin, J.-R., Kapil, L., Tsai, H.-A., Liao, W.-C., Chou, Y.-C., & Liu, C.-H. (2026). Revisiting human circulating γδ T cells: developmental insights and manufacturing challenges for cancer immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04561-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04561-2

Keywords: gamma-delta T cells, adoptive cell therapy, cancer immunotherapy, cellular senescence, immune aging, ex vivo expansion, single-cell RNA sequencing, CAR-gamma-delta T cells, mitochondrial dysfunction, senolytics, dasatinib, solid tumors

One intriguing avenue of exploration is the use of gamma-delta (γδ) T cells as a more versatile alternative for CAR T cell therapy. Unlike conventional T cells, γδ T cells exhibit distinct properties that could be harnessed for ‘off-the-shelf’ therapies. Their innate ability to recognize stress-induced ligands allows them to exhibit anti-tumor activity more broadly, which could revolutionize the way we approach cancer immunotherapy. However, the road to clinical translation for γδ CAR T cells has not been devoid of obstacles. Key issues including their naturally low frequency in peripheral blood, resistance to efficient genetic manipulation, and the advanced differentiation state achieved during ex vivo expansion present a formidable challenge to researchers.

In a groundbreaking study, researchers have made significant strides in overcoming these barriers by demonstrating a novel method for the in vitro activation and expansion of peripheral blood γδ T cells. By optimizing the activation conditions and employing specific techniques, the research aims to achieve high gene editing efficiencies and effective CAR integration. This approach consists of the use of artificial antigen-presenting cells, which are designed to create an optimal environment for the proliferation and functionality of γδ T cells. Such advancements are pivotal in producing minimally differentiated and highly functional γδ CAR T cells ready for therapeutic applications.

One of the most compelling developments reported in this research focuses on the targeting of CCR5, a gene commonly implicated in both cancer progression and HIV infection. By integrating a US Food and Drug Administration-approved CD19 CAR into the CCR5 locus, the researchers generated a unique population of CCR5-deficient γδ CD19 CAR T cells, designated as γδ CCR5KI-CAR19 T cells. The strategic targeting of CCR5 not just enhances the anti-tumor potential of these CAR T cells, but also confers important HIV-mediated resistance, proposing a dual therapeutic strategy against HIV-associated B cell malignancies.

In experimental models, γδ CCR5KI-CAR19 T cells displayed remarkable resilience against HIV-induced depletion, showcasing a wider therapeutic spectrum for patients suffering from both HIV and B cell malignancies. The findings highlight an essential intersection between immunology, virology, and oncology, granting a new lease on life to strategies currently employed in treating complex cases of malignancy associated with viral infections. Moreover, the efficiency of γδ CAR T cells in mounting a robust antitumor response against B cell lymphoma and leukemia was evident in preclinical settings.

This innovative approach sets the stage for a new paradigm of robust and cost-effective cancer therapies that stem from allogeneic sources. The fact that γδ CAR T cells could be produced from a healthy donor’s immune cells not only expands the availability of these therapies but also reduces the burdensome logistics associated with personalized therapies. The potential for large-scale development of allogeneic γδ CAR T cells points towards a sustainable blueprint for future immunotherapy options that can be deployed swiftly to meet patient needs.

As the study unfolds, it is essential to emphasize that preclinical evidence serves as groundwork for pursuing clinical trials. This transition is crucial, as it determines how well the therapeutic strategies translate into human applications, which can vary significantly from models showing efficacy in vitro. Researchers are now poised to embark on rigorous clinical testing to validate the safety and effectiveness of γδ CCR5KI-CAR19 T cells, ensuring they meet regulatory standards while providing genuine therapeutic benefits to patients.

In light of the preclinical success reported, the implications of utilizing γδ CAR T cells extend beyond just HIV-associated B cell malignancies. The inherent qualities of γδ T cells suggest they could potentially be adapted against a variety of other malignancies, paving the way for more expansive applications within cancer therapies. Such flexibility enhances their appeal in the rapidly diversifying landscape of personalized oncology treatments, where tailored strategies and combination approaches are on the rise.

As the scientific community continues to navigate the complexities of cancer treatment and the interplay with viral infections, the advancements in γδ CAR T cell technology represent a beacon of possibility. The commitment to innovating therapies by targeting both cancer and viral paths allows a more comprehensive understanding of tumor biology and ultimately aims to mitigate the burden of disease on patients and healthcare systems alike.

Further, the meticulous exploration of these innovative technologies invites increased collaboration across disciplines, setting a collaborative tone for addressing multifactorial diseases like cancer that are often compounded by co-infections such as HIV. The integration of research initiatives focusing on these aspects is paramount as stakeholders work collectively to ensure that advancements are translated into tangible benefits for patients.

Overall, the research highlights a paradigm shift in our approach to cancer therapies, demonstrating that by rethinking traditional notions of CAR T cell therapy, we can harness the full potential of γδ T cells. As the landscape of immunotherapy continues to evolve, the dynamic contributions of γδ CAR T cells stand poised to play a pivotal role in reshaping the future of cancer treatment, particularly for those afflicted with complexities arising from co-existing conditions.

The forthcoming years will likely witness the realization of these preclinical visions, ultimately leading to novel therapeutic interventions that can save lives. The supportive evidence produced in this study will be indispensable for building a broader framework for understanding the limitations of current therapies and discovering new strategies that hold promise against formidable challenges in oncology.

Subject of Research: Gamma-delta CAR T cells for HIV-associated B cell malignancy immunotherapy.

Article Title: CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.

Article References:

Ramírez-Fernández, Á., Dimitri, A.J., Chen, F. et al. CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.
Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01527-0

Image Credits: AI Generated

DOI:

Keywords: CAR T cell therapy, gamma-delta T cells, HIV, B cell malignancies, immunotherapy, gene editing, CCR5, cancer treatment.

T-cells, crucial components of the adaptive immune system, rely on finely tuned intracellular signaling cascades for activation and proliferation. Previous studies have illuminated that cross-linking the T-cell receptor triggers a burst of reactive oxygen species within mitochondria, a phenomenon indispensable for antigen-specific T-cell proliferation. Paradoxically, this oxidative burst carries the risk of causing cellular damage, tempering the overall efficacy and viability of expanding T-cell populations—a delicate balance the new study sought to manipulate.

The international research team focused on γδ T-cells, a subset of T-cells characterized by their distinct γδ T-cell receptor, known for their rapid response to infection and tumors without the need for antigen presentation via major histocompatibility complex (MHC) molecules. This attribute makes γδ T-cells promising candidates for adoptive T-cell therapies, especially for treating cancers that evade conventional immune detection. However, the optimization of their expansion ex vivo without compromising function remains a clinical challenge.

To address this, peripheral blood mononuclear cells (PBMCs)—the cellular foundation for generating T-cell populations—were cultured in the presence or absence of key antioxidants commonly known for their ROS-scavenging properties: N-acetyl cysteine (NAC), vitamin C, and vitamin E. These antioxidants were carefully administered during the induction and expansion stages to evaluate their impacts on the proliferation, phenotype, and cytolytic abilities of γδ T-cells against bladder cancer cells.

Intriguingly, NAC exhibited a dose-dependent inhibitory effect on overall T-cell expansion, a finding underscoring the complexity of redox balance in T-cell biology. High concentrations of NAC partially suppressed the proliferation of CD3⁺/Vγ9⁺ cells, a principal subset of γδ T-cells, suggesting that excessive ROS inhibition may impair the critical signaling processes needed for optimal T-cell growth. This nuanced role of NAC prompts reconsideration of blanket antioxidant use during immune cell cultivation.

Vitamin E treatment presented a distinct immunomodulatory profile. While it moderately reduced the levels of CD3⁺/CD56⁺ natural killer (NK)-like T-cells and decreased the expression of the activating receptor CD314 (NKG2D), it did not hinder overall expansion as markedly as NAC. Given that NKG2D plays a pivotal role in recognizing and destroying stressed or transformed cells, this reduction hints at a subtle trade-off between antioxidant-mediated protection and effector receptor expression, motivating further investigation into dosing strategies.

Perhaps most compellingly, the study demonstrated that co-incubating γδ T-cells expanded with antioxidants alongside bladder cancer cells resulted in significantly enhanced tumor cell cytolysis. This observation suggests that antioxidants can improve the functional quality of these immune cells, potentially by mitigating oxidative damage during expansion and preserving cytotoxic mechanisms. The ability to augment T-cell mediated killing of urothelial carcinoma cells heralds promising implications for developing more effective adoptive cell therapies.

Urothelial carcinoma, a malignancy with high mortality particularly among men globally, desperately requires innovative treatment approaches. Immunotherapy using autologous or allogeneic T-cell populations offers a beacon of hope but is hindered by challenges in producing sufficient numbers of highly functional cells. The novel insights from this antioxidant-focused study pave the way to refine expansion protocols that balance proliferation, survival, and antitumor activity.

Mitochondrial health, often compromised by oxidative stress during ex vivo T-cell culture, appears to be a decisive factor influencing the success of adoptive therapies. Antioxidants, by modulating ROS metabolism, may protect mitochondria from injury without completely abolishing the ROS signaling necessary for T-cell activation. This delicate interplay underscores the critical need for precision medicine approaches in cellular immunotherapy manufacturing.

The distinction between how various antioxidants impact different T-cell subsets and receptors also opens new avenues for customized immune cell engineering. For instance, selective use of vitamin E might be strategized to fine-tune NK-like γδ T-cell populations, while careful dosing of NAC could prevent over-suppression of essential proliferative signals, optimizing therapeutic outcomes.

Beyond bladder cancer, the implications of this research extend to other malignancies where γδ T-cells may serve as key players in immune surveillance. The findings encourage broader exploration of redox modulation as a universal enhancer of T-cell based immunotherapies, potentially revolutionizing treatment in hematologic and solid tumors alike.

As the immuno-oncology field races to adopt cell-based approaches, integrating functional antioxidants during ex vivo expansion protocols could become a standard practice, improving the shelf-life, safety, and potency of engineered T-cell products. This advancement holds promise not only for augmenting clinical response rates but also for reducing manufacturing costs by boosting yield and functionality simultaneously.

Future studies are anticipated to dissect the molecular pathways by which antioxidants influence T-cell metabolism, receptor expression, and cytolytic machinery. Such mechanistic insights will enable the design of next-generation culture media and supplements, tailored to nurturing the most effective cellular soldiers against cancer.

Equally important will be translating these in vitro findings into clinical trials to assess safety, efficacy, and optimal dosing in patients. The transition from bench to bedside will require collaboration across immunologists, oncologists, and biotechnologists to harness the full therapeutic potential of antioxidant-augmented γδ T-cell therapies.

In summation, this pioneering research sheds light on a hitherto underappreciated axis within T-cell immunobiology—the controlled modulation of oxidative stress to enhance cellular therapy success. The strategic co-administration of antioxidants emerges as a promising lever to steer the balance towards more robust, resilient, and effective γδ T-cell populations in the fight against bladder and potentially other cancers.

Subject of Research: Effects of functional antioxidants on γδ T-cell proliferation and cytotoxicity against urothelial carcinoma cells.

Article Title: Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells.

Article References:
Pan, Y., Shih, HJ., Chuang, SH. et al. Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells. BMC Cancer 25, 980 (2025). https://doi.org/10.1186/s12885-025-14383-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14383-7